CSG

What CSG does

CSG Clinische Studien Gesellschaft mbH is a Berlin-based full-service Contract Research Organization (CRO) and a wholly-owned subsidiary of IGES Group, operating under the broader Athagoras umbrella alongside affiliated entities including IGES Institut, IMC clinicon, HealthEcon, Assessment in Medicine, Device Access UK, Optimax Access, and MediTech Access. Founded circa 2010 and headquartered at Friedrichstraße 180, the firm serves pharmaceutical, biotechnology, and medical device manufacturers across Germany and Europe with end-to-end clinical research services spanning Phase II–IV interventional trials, non-interventional/post-authorization safety studies, biomarker research, and MDR-compliant medical device investigations. Since 2023 it has also built out a dedicated pharmacovigilance service line covering QPPV provision, signal management, SUSAR reporting, DSMB participation, PSUR/DSUR creation, and risk management plan development.

The company's technology stack is anchored on an Oracle Clinical RDC Electronic Data Capture system certified to 21 CFR Part 11 for secure clinical data storage and processing, supplemented by a licensed MedDRA system for adverse event coding. Service execution is supported by in-house capabilities in regulatory affairs, biostatistics, medical writing, monitoring (including risk-based and remote), and data management, with patient recruitment handled through IMC clinicon. CSG's go-to-market is project-based B2B contracting with sponsors; the firm explicitly markets its positioning as a specialist CRO with the breadth of a full-service provider, leveraging IGES Group synergies for evidence generation, health economics, and market access. A notable recent milestone is the November 2025 commissioning by the German G-BA (together with Gesundheitsforen Leipzig) to sponsor the BALDIKA §137h Erprobungsstudie of a balloon dilation catheter across ~460 patients at 25 German centers, marking its entry into publicly-funded real-world evidence research.

Leadership is physician-led, with CEO Dr. Marc Kurepkat (MD, specialist in general medicine, doctorate in infectious diseases) bringing both clinical practice and IGES Group tenure since 2001. The firm's customer base is described in sectoral terms — pharma, biotech, medical device, and vaccine manufacturers — rather than via named accounts, and revenue is project-driven and episodic. No public pricing exists; commercial terms are negotiated per study scope and duration.

Name

CSG

Legal name

CSG Clinische Studien Gesellschaft mbH

Website

https://csg-germany.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Berlin-based full-service Contract Research Organization (CRO) and IGES Group subsidiary offering Phase II–IV clinical trials, non-interventional studies, biomarker research, medical device investigations, and pharmacovigilance services to pharmaceutical, biotech, and medical device manufacturers across Germany and Europe.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Clinical research services
• Contract research organization
• Pharmacovigilance services
• Medical device trials
• Clinical data management

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. SaaS Platform Services: Recurring SaaS subscription and service fees for billing, payment processing, and customer care platform serving telecom and satellite providers. Long-term contracts provide stable recurring revenue with the DISH partnership extending through 2030.
2. Enterprise Software Licenses and Services: Configure, Price, Quote (CPQ) software solutions and related professional services for communication service providers managing complex B2B enterprise deals

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

CSG Clinische Studien Gesellschaft mbH is a full-service Contract Research Organization (CRO) that plans, conducts, and analyzes clinical-scientific studies for pharmaceutical, biotechnology, and medical device manufacturers. Its portfolio covers Phase II–IV pharmaceutical trials, non-interventional/post-authorization safety studies, medical device trials under MDR, biomarker studies, and pharmacovigilance/risk management services.

Product overview

CSG Clinische Studien Gesellschaft operates as a Full-Service Contract Research Organization (CRO) providing end-to-end clinical research services. The company offers a comprehensive portfolio of study types including clinical trials for pharmaceuticals and medical devices, non-interventional studies, and biomarker research. Supporting services include pharmacovigilance, regulatory affairs, data management (using Oracle Clinical RDC with EDC systems), monitoring, statistics, medical writing, and project management. As part of the IGES Group for over 20 years, CSG leverages synergies with complementary research fields including IGES Institut (healthcare research), IMC clinicon (hospital analysis), HealthEcon (health economics), Assessment in Medicine (medical technology), and Device Access UK to deliver tailored project outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials for Pharmaceuticals

Quantifiable outcome

• CSPs cut deployment times with CSG CPQ platform
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Polska Grupa Zbrojeniowa S.A. (PGZ)flagshipStrategic or Co-development Partner · 11 March 2026Framework Cooperation Agreement signed March 2026 to collaborate on multidomain defence projects including engines for unmanned systems, missiles, ammunition, and land platforms. Partnership aims to enhance industrial, technological, and production capabilities within Europe, focusing on regional security and supply chain resilience.
• Polska Grupa Zbrojeniowa S.A. (PGZ)flagshipStrategic or Co-development Partner · 1 February 2026Cooperation agreement for development and export of modular mining deployment system. Strategic partnership expanding CSG's European defence industrial footprint alongside Munich Security Conference industrial partnership role.
• Munich Security ConferenceflagshipStrategic or Co-development Partner · 1 February 2026CSG became first Czech company—and likely first from Central and Eastern Europe—to achieve partnership status at the Munich Security Conference. Partnership reflects strategic presence in both Europe and the United States and commitment to strengthening transatlantic cooperation amid Russia's ongoing aggression against Ukraine.
• DISH NetworkcoreStrategic or Co-development Partner · 28 January 2026Multi-year contract extension through 2030 ensuring continued billing, payment processing, and customer service operations for DISH's millions of subscribers. CSG has served as DISH's billing and payment services partner for three decades, making this one of the company's most strategic and longest-standing relationships.
• DISH NetworkcoreStrategic or Co-development Partner30-year partnership milestone achieved in January 2026 with contract extension through 2030. CSG powers core operational processes including billing, payment processing, and customer service solutions through its SaaS platform.

Scale indicators7 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Syneos Health: Large global biopharmaceutical solutions organization spanning clinical development, commercial, and consulting — comparable clinical operations and PV capabilities to CSG but with significantly broader service portfolio and global footprint.
• ICON plc: One of the world's largest CROs providing clinical research, biometric, laboratory, and pharmacovigilance services globally. Comparable on the PV and full-service clinical operations side, but at vastly larger scale and global reach.
• Parexel International: Major global CRO with deep expertise in clinical operations, biostatistics, regulatory affairs, and pharmacovigilance across pharma and medical device clients — covering the same service surface as CSG but at global mega-CRO scale.
• Medpace: Mid-to-large global CRO offering full-service Phase I–IV clinical operations, biostatistics, PK/PD, and medical device services to pharma and biotech sponsors. Operates at significantly larger scale than CSG but overlaps in therapeutic breadth and sponsor type.
• Worldwide Clinical Trials: Mid-to-large global CRO offering Phase I–IV clinical operations, biostatistics, medical device, and pharmacovigilance services — comparable service surface to CSG but with broader geographic reach and deeper sponsor relationships.
• IQVIA: The world's largest CRO and RWE provider, combining clinical operations with real-world data analytics, HEOR, and technology platforms. Closely comparable to CSG's clinical-plus-RWE positioning, but at global incumbent scale.
• Charles River Laboratories: Global CRO and preclinical/services organization offering clinical trial support, biostatistics, regulatory, and laboratory services across pharma, biotech, and medical device sectors. Comparable breadth of services but substantially larger scale.
• SGS Health & Nutrition: Global life sciences services provider running clinical research, pharmacovigilance, laboratory, and certification services for pharma, medical device, and biotech clients. Comparable in clinical and PV service offering but with global infrastructure.

Direct peers

• NAMSA: Global medical device-focused CRO that runs regulatory and clinical trial programs under EU MDR and FDA frameworks — directly overlapping CSG's medical device clinical investigation offering for European sponsors.
• FGK Clinical Research GmbH: Munich-based full-service European CRO of comparable size and scope, conducting Phase I–IV trials, medical device studies, and pharmacovigilance services across the DACH region. Directly comparable specialty CRO serving German pharma and medical device sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/csg-klinische-studiengesellschaft

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSG